Cataract MatureNCT07654387
Divide and Conquer With Debulking in Management of Rocky Hard Cataract
A study testing cataract operation by phacoemulsification in people with Cataract Mature, run by Sohag University.
Trial summary
The management of nucleus may be challenging in rocky hard cataracts. Hard cataracts are difficult to fragment, and the excessive energy required to emulsify the hard nucleus can result in complications such as corneal edema, inflammation, wound burn, posterior capsular rupture, and zonular dialysis. Read more about this study
- Who is it for?
- Ages 40 to 100 years
- Conditions the study is for
- Cataract Mature
- What is being tested?
- cataract operation by phacoemulsification
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Jul 2026to 1 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- adults with rocky hard cataract
Who cannot join
- patients with abnormal endothelial cell count.
- patients with glaucoma.
- patients with retinal problems.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The management of nucleus may be challenging in rocky hard cataracts. Hard cataracts are difficult to fragment, and the excessive energy required to emulsify the hard nucleus can result in complications such as corneal edema, inflammation, wound burn, posterior capsular rupture, and zonular dialysis. different surgical techniques are used for the management of hard cataracts, with their advantages and limitations. Divide and conquer with debulking is a new technique for management of rocky hard cataract.
In this research we assess its safety comparing it with standard divide and conquer technique.
Read the detailed description
The management of nucleus may be challenging in rocky hard cataracts. Hard cataracts are difficult to fragment, and the excessive energy required to emulsify the hard nucleus can result in complications such as corneal edema, inflammation, wound burn, posterior capsular rupture, and zonular dialysis. different surgical techniques are used for the management of hard cataracts, with their advantages and limitations. Divide and conquer with debulking is a new technique for management of rocky hard cataract.
In this research we assess its safety comparing it with standard divide and conquer technique.
- Conditions
- Cataract Mature
- Being tested
- cataract operation by phacoemulsification
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cataract operation by phacoemulsificationProcedure or surgery
phacoemulsification either by standard divide and conquer or divide and conquer with debulking.
| Study group | Role | What they receive |
|---|---|---|
| standard divide and conquer | Active comparator | patients with rocky hard cataract will undergo standard divide and conquer technique Receives: Procedure: cataract operation by phacoemulsification |
| divide and conquer with debulking | Experimental | patients with rocky hard cataract will undergo divide and conquer with debulking technique Receives: Procedure: cataract operation by phacoemulsification |
What is being measured
The primary outcome is the main question the study is designed to answer.
endothelial cell count
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start1 Jul 2026 (estimated)
- Primary completion1 Oct 2026 (estimated)
- Study completion1 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cataract MatureStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hany Mahmoud,MD, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07654387
- Sponsor's protocol ID
- Soh-Med-26-5-3PD
- Status last verified
- Jun 2026
- First submitted
- 13 Jun 2026
- Last updated
- 17 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Divide and Conquer With Debulking in Management of Rocky Hard Cataract
- ClinicalTrials.gov ID
- NCT07654387
- Acronym / sponsor ID
- Soh-Med-26-5-3PD
- Conditions
- Cataract Mature
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Jul 2026 (estimated)
- Primary completion
- 1 Oct 2026 (estimated)
- Study completion
- 1 Nov 2026 (estimated)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The management of nucleus may be challenging in rocky hard cataracts. Hard cataracts are difficult to fragment, and the excessive energy required to emulsify the hard nucleus can result in complications such as corneal edema, inflammation, wound burn, posterior capsular rupture, and zonular dialysis. different surgical techniques are used for the management of hard cataracts, with their advantages and limitations. Divide and conquer with debulking is a new technique for management of rocky hard cataract.
In this research we assess its safety comparing it with standard divide and conquer technique.
Detailed description
The management of nucleus may be challenging in rocky hard cataracts. Hard cataracts are difficult to fragment, and the excessive energy required to emulsify the hard nucleus can result in complications such as corneal edema, inflammation, wound burn, posterior capsular rupture, and zonular dialysis. different surgical techniques are used for the management of hard cataracts, with their advantages and limitations. Divide and conquer with debulking is a new technique for management of rocky hard cataract.
In this research we assess its safety comparing it with standard divide and conquer technique.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| standard divide and conquer | Active comparator | Procedure: cataract operation by phacoemulsificationpatients with rocky hard cataract will undergo standard divide and conquer technique |
| divide and conquer with debulking | Experimental | Procedure: cataract operation by phacoemulsificationpatients with rocky hard cataract will undergo divide and conquer with debulking technique |
Who may qualify
- Ages
- 40 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- adults with rocky hard cataract
Key exclusion criteria (3 listed)
- patients with abnormal endothelial cell count.
- patients with glaucoma.
- patients with retinal problems.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cataract operation by phacoemulsificationphacoemulsification either by standard divide and conquer or divide and conquer with debulking. | Procedure or surgery | divide and conquer with debulking, standard divide and conquer |
Primary outcome
endothelial cell count
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
- Individual participant dataSharing planned: Yes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing cataract operation by phacoemulsification in people with Cataract Mature, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hany Mahmoud (01024368111, drhanymahmoud@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
endothelial cell count (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026; AzTrials last refreshed its copy on 7 Nov 2026.